18F-FDG PET/CT在妇科恶性肿瘤中的临床应用价值

目的:探讨18F-FDGPET/CT在妇科恶性肿瘤诊断及随访中的应用价值。方法:对33例妇科恶性肿瘤患者(17例原发肿瘤、16例术后可疑复发或转移)行18F-FDGPET/CT显像,与常规影像学结果进行分析比较。结果:17例原发肿瘤患者中,PET/CT和常规影像学对原发病灶的诊断无统计学差异;两种方法对淋巴结转移的诊断敏感性、特异性、准确性、阳性预测值和阴性预测值分别为:85.7%vs28.6%,100%vs100%,94.1%vs70.6%,100%vs100%和90.9%vs66.7%,两者比较敏感性有统计学差异;对转移淋巴结数目的诊断准确性分别为92.3%,46.2%,两者比较有统计学差异。16例可疑复发或转移患者中,PET/CT及常规影像学对病例数的诊断无统计学差异,对病灶数目的诊断敏感性、特异性、准确性、阳性预测值及阴性预测值分别为:76.9%vs48.7%,77.8%vs66.7%,77.1%vs52.1%,93.8%vs86.4%及43.8%vs23.1%,两者比较敏感性、准确性有统计学差异。结论:18F-FDGPET/CT作为一种有效的无创性影像学诊断方法,在妇科恶性肿瘤的诊断及随访过程中具有重要的临床应用价值。

Diagnostic Value of 18F-FDG PET/CT for Gynecological Malignancies

Objective:To investigate the diagnostic value of 18 F-FDG PET/CT in pre-operative diagnosis and post-operative follow-up of gynecological malignancies.Materials and Methods:33 patients(17 patients who were doubted malignant tumors and 16 patients who were suspected recurrence or metastasis after operation)were scanned by 18 F-FDG PET/CT.The results were compared with the conventional imaging modalities.Results:In 17 patients who were doubted malignant tumors,the patients-based diagnostic ability of PET/CT was similar with conventional imaging modalities.For metastasis diagnosis,the sensibility,specificity,accuracy,positive predictive value and negative predictive value of the two methods were 85.7%vs 28.6%,100%vs 100%,94.1%vs 70.6%, 100%vs 100%,90.9%vs 66.7%.The sensibility of the two methods had significant difference.And the lesion-based accuracy of PET/CT for metastasis was also significantly higher.In 16 patients who were suspected recurrence or metastasis after operation,The lesion-based sensibility,specificity,accuracy,positive predictive value and negative predictive value of the two methods were 76.9%vs 48.7%,77.8%vs 66.7%,77.1%vs 52.1%, 93.8%vs 86.4%,43.8%vs 23.1%.The sensibility and accuracy of PET/CT were higher than that of conventional imaging modalities significantly.Conclusion: 18 F-FDG PET/CT,as a non-invasive imaging modality,has considerable value in pre-operative diagnosis and post-operative follow-up of of gynecological malignancies.